ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023
An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- The State-of-the Art of Personalized Vaccines for Non-Communicable Diseases: A Narrative Review.Vaccines · 2026Review
- Enhanced Anti-Lung Cancer Efficacy of Neo-BCV Combined with Cisplatin: Immune Activation and Tumor Microenvironment Remodeling.Vaccines · 2026Article
- Recent progress of dendritic cell-derived exosomes in tumor immunotherapy.Investigational new drugs · 2026Review
- Exosome-based vaccines in cancer immunotherapy: antitumor mechanisms, engineering strategies, and challenges.Journal of cancer research and clinical oncology · 2026Review
- Engineering BiTE-inspired IPSC-exosomes to potentiate CAR-T cell therapy against lung cancer.Journal of nanobiotechnology · 2026Article
- Engineered nanovesicles as a DC vaccine to enhance the antitumor efficacy of CAR-T cells against solid tumors.Journal of nanobiotechnology · 2026Article
- The avatar principle: exosomal dynamics guiding tumor adaptation and next-generation therapeutic strategies.Journal of nanobiotechnology · 2026Review
- A Macrophage/Monocyte-Related Four-Gene Signature for Prognostic Assessment of Uveal Melanoma:Human mutation · 2026Article
- Orchestrating Tumor Metastasis: Exosomes as Master Regulators of the Local and Distant Microenvironment.International journal of biological sciences · 2026Review
- Exosome Augmentation Technologies for Drug Delivery and Disease Treatment: A Review.Biomaterials research · 2026Review
- Insights into extracellular vesicle-based platforms on the way to cancer treatment.Journal of translational medicine · 2025Review
- Clinical relevance of extracellular vesicles in cancer - therapeutic and diagnostic potential.Nature reviews. Clinical oncology · 2025Review
- Unveiling the intricacies of exosome biology: from biogenesis to therapeutic applications.Histochemistry and cell biology · 2025Review
- Review
- Progress in the development of cancer vaccines for lung cancer utilizing dendritic cells (Review).Oncology letters · 2025Review
- Article
- Lactiplantibacillus plantarum -derived extracellular vesicles alleviate acute lung injury by inhibiting ferroptosis of macrophages.Journal of nanobiotechnology · 2025Article
- Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy.Archives of dermatological research · 2025Review
- The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles.Vaccines · 2025Review
- Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates.Immunotherapy · 2025Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cells (iPSCs) express a broad spectrum of tumor-associated antigens and exert prophylactic effects on various tumors. However, some problems remain, such as potential tumorigenicity, challenges in transport to the lymph nodes and spleen, and limited antitumor effects. Thus, designing a safe and effective iPSC-based tumor vaccine is necessary. We prepared iPSC-derived exosomes and incubated them with DCs (dendritic cells) for pulsing to explore their antitumor effects in murine melanoma models. The antitumor immune response induced by the DC vaccine pulsed with iPSC exosomes (DC + EXO) was assessed in vitro and in vivo. After DC + EXO vaccination, extracted spleen T cells effectively killed a variety of tumor cells (melanoma, lung cancer, breast cancer, and colorectal cancer) in vitro. In addition, DC + EXO vaccination significantly inhibited melanoma growth and lung metastasis in mouse models. Furthermore, DC + EXO vaccination induced long-term T cell responses and prevented melanoma rechallenge. Finally, biocompatibility studies showed that the DC vaccine did not significantly alter the viability of normal cells and mouse viscera. Hence, our research may provide a prospective strategy of a safe and effective iPSC-based tumor vaccine for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.